Equity Overview
Price & Market Data
Price: $2.59
Daily Change: +$0.09 / 3.47%
Daily Range: $2.51 - $2.67
Market Cap: $5,939,665
Daily Volume: 8,964
Performance Metrics
1 Week: 4.88%
1 Month: 1.18%
3 Months: -43.84%
6 Months: -87.71%
1 Year: -88.24%
YTD: -45.21%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.